title: Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma?
abstract: BACKGROUND
  The extent of lymphadenectomy and protocol design in gastric cancer trials limits interpretation of survival benefit of adjuvant therapy after surgery with adequate lymphadenectomy. We examined the impact of surgery with adequate nodal evaluation alone on gastric cancer survival.
  
  
  METHODS
  Using 2001-2008 California Cancer Registry, we identified 2,229 patients who underwent gastrectomy with adequate nodal evaluation (≥15 lymph nodes) for American Joint Committee on Cancer stage I-IV M0 gastric adenocarcinoma. Cox proportional hazard analyses were used to evaluate the impact of surgery alone on survival.
  
  
  RESULTS
  Nearly 70% of our cohort had T1/2 tumors and 29% had N0 disease. Forty-nine percent of the cohort underwent surgery alone. These patients were more likely to be older, Medicare-insured, with T1 and N0 disease. On unadjusted analyses, persons who underwent surgery alone for stage I or N0 disease experienced 1- and 3-year overall and cancer-specific survival comparable to those who received adjuvant therapy. On multivariate analyses for stage I or N0 disease, surgery alone predicted superior survival outcomes than when combined with adjuvant therapies.
  
  
  CONCLUSIONS
  Surgery alone with adequate nodal evaluation may have a role in low-risk gastric cancer. To corroborate these findings, surgery with adequate lymphadenectomy alone (as treatment arm) deserves consideration in the design of gastric cancer trials to provide effective yet resource-conserving, rather than maximally tolerated, treatments.
authors.affiliation: University of Minnesota Surgical Outcomes Research Center, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
authors.forename: Vikas
authors.initials: V
authors.lastname: Dudeja
authors.forename: Elizabeth B
authors.initials: EB
authors.lastname: Habermann
authors.forename: Anasooya
authors.initials: A
authors.lastname: Abraham
authors.forename: Wei
authors.initials: W
authors.lastname: Zhong
authors.forename: Helen M
authors.initials: HM
authors.lastname: Parsons
authors.forename: Jennifer F
authors.initials: JF
authors.lastname: Tseng
authors.forename: Waddah B
authors.initials: WB
authors.lastname: Al-Refaie
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D005260:Female; D005743:Gastrectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
references.citation: Ann Surg. 2000 Sep;232(3):362-71
references.pmid: 10973386
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2759-61
references.pmid: 15199086
references.citation: Cancer. 2010 Jan 15;116(2):465-75
references.pmid: 19950130
references.citation: Ann Surg Oncol. 2009 Oct;16(10):2738-43
references.pmid: 19636636
references.citation: Cancer. 2000 Feb 15;88(4):921-32
references.pmid: 10679663
references.citation: Surg Oncol Clin N Am. 2010 Jan;19(1):81-100
references.pmid: 19914561
references.citation: N Engl J Med. 2001 Sep 6;345(10):725-30
references.pmid: 11547741
references.citation: J Natl Cancer Inst. 2008 Mar 19;100(6):388-98
references.pmid: 18334706
references.citation: Ann Surg Oncol. 2007 Feb;14(2):317-28
references.pmid: 17094022
references.citation: Br J Cancer. 1999 Mar;79(9-10):1522-30
references.pmid: 10188901
references.citation: Ann Oncol. 2000 Jul;11(7):837-43
references.pmid: 10997811
references.citation: Ann Surg Oncol. 2002 Apr;9(3):278-86
references.pmid: 11923135
references.citation: Surg Oncol Clin N Am. 2002 Apr;11(2):445-58
references.pmid: 12424862
references.citation: J Clin Oncol. 2004 Nov 15;22(22):4567-74
references.pmid: 15542808
references.citation: Ann Surg Oncol. 2011 Jan;18(1):26-33
references.pmid: 20645007
references.citation: Ann Surg. 2010 Feb;251(2):311-8
references.pmid: 19838107
references.citation: Ann Surg Oncol. 2010 Dec;17(12):3173-80
references.pmid: 20585870
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7114-24
references.pmid: 16192595
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2069-77
references.pmid: 15082726
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: World J Gastroenterol. 2006 Jan 21;12(3):354-62
references.pmid: 16489633
references.citation: Ann Surg Oncol. 2010 Jul;17(7):1732-8
references.pmid: 20354801